Related Experiment Video
Updated: Jul 6, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Blastic mantle cell lymphoma with a Burkitt translocation
Kavita Reddy1, Mohammad Ansari-Lari, Bruno Dipasquale
1Genzyme Genetics, NY 10019, USA. kavita.reddy@gmail.com
Leukemia & Lymphoma
|April 10, 2008
Summary
MYC gene rearrangements define an aggressive subtype of blastic mantle cell lymphoma (MCL) with Burkitt features. This rare variant presents with poor prognosis, potentially necessitating Burkitt lymphoma treatment protocols.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma.
- Blastic transformation in MCL represents an aggressive subtype.
- MYC gene rearrangements are implicated in certain aggressive lymphomas.
Observation:
- Two patients presented with blastoid morphology and significant peripheral blood lymphocytosis or bone marrow blasts.
- Both patients exhibited concurrent CCND1/IGH and MYC gene rearrangements.
- Immunophenotyping revealed CD5+, CD10+, CD20+, CCND1+, and a high Ki-67 proliferation index (>90%).
Findings:
- The cases were diagnosed as blastic MCL with Burkitt features.
- The genetic profile (MYC rearrangement) and morphology suggest a distinct aggressive MCL entity.
- These findings align with previously reported cases of aggressive blastic MCL.
Implications:
- This aggressive subtype of blastic MCL has a poor prognosis.
- Treatment strategies may need to incorporate protocols typically used for Burkitt lymphoma.
- Further research is warranted to define optimal therapeutic approaches for this rare variant.
